These tweets are selected automatically with #rstats code. Please inform me if any is inappropriate. See other #HemePath pages here: https://serdarbalci.netlify.com/categories/HemePath/ or here: https://serdarbalci.wordpress.com/?s=HemePath/ See selected social media based textbook project here: http://www.patolojinotlari.com/
Aggressive NK cell leukemia. HE and Gross (para-aorta LN). pic.twitter.com/izEba0tJgl
— Pathology Walker@Auto Tweet Bot (@Patholwalker) December 21, 2018
get them ready for DIC!!
— Larkin Walker (@lfwalkerlw) April 12, 2020
Today, in #HumpDayHemepath - What diagnosis are you considering in this marrow from an HIV+ patient with cytopenias? Poll below #VirtualPath #Pathology #Hemepath #MedStudentTwitter @loyolapathology @LoyolaOnc @LoyolaHemePath @MLSatLoyola #PathBoards pic.twitter.com/x284Fc5ZxW
— Kamran Mirza MD PhD (@KMirza) April 1, 2020
RT PhysRelations "RT sanamloghavi: Dr. Hong Fang from MDAndersonNews #HemepathMDA presenting data on MDS and AML with t(6;9) suggesting Allo-HSCT abrogates the difference in survival between the MDS and AML groups. #leusm #USCAP2020 pic.twitter.com/kkPHclh6OI"
— Robert Z. Orlowski (@Myeloma_Doc) March 3, 2020
RT PhysRelations "RT TashakoriM: Happening now: precision Dx and modern Tx in AML by amazing Dr. Bueso-Ramos and Dr. Daver_Leukemia from MDAndersonNews #USCAP2020 #Leukemia pic.twitter.com/ijyn6loVPj"
— Robert Z. Orlowski (@Myeloma_Doc) March 3, 2020
9p24.1/PDL1 Amplification and Checkpoint Molecule Expression in T-Cell Lymphomas#USCAP2020 https://t.co/6GavKvkitP
— Julie Feldstein,M.D., FCAP (@feldstej) March 2, 2020
LACC 403 A
Platform
Peripheral T-Cell Lymphomas are Characterized by Transcriptionally Active FOXO3
— Julie Feldstein,M.D., FCAP (@feldstej) March 2, 2020
#USCAP2020
LACC West Exhibit Hall A
Poster 286 Presentation https://t.co/tBzRE9gUPO pic.twitter.com/DCMomLRg1B
Utility of Lymphoid Enhancer-Binding Factor -1 (LEF-1) Expression by Immunohistochemistry in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
— Julie Feldstein,M.D., FCAP (@feldstej) March 2, 2020
#USCAP2020
LACC West Exhibit Hall A
Poster 292 Presentation https://t.co/tBzRE9gUPO pic.twitter.com/vsfmS4iNKk
Features of Hepatic Lymphoma: A 16-Year Retrospective Study on 90 Patients from a Single Center #USCAP2020
— Julie Feldstein,M.D., FCAP (@feldstej) March 2, 2020
https://t.co/tBzRE9gUPO
LACC West Exhibit Hall A
Poster 288 Presentation Stowell Orbison
Comparison of the Performance of Two Different ALK Antibody Clones (D5F3 and ALK1) in Anaplastic Large Cell Lymphoma (ALCL)
— Julie Feldstein,M.D., FCAP (@feldstej) March 2, 2020
#USCAP2020
LACC West Exhibit Hall A
Poster 305 Presentation
Primary Cutaneous Composite Lymphomas; read this research by Dr. Stephanie Chen (@uihealthcare) and Drs. Daniel Boyer and Hristov (@UMichPath) in the current @ArchivesPath: https://t.co/fWUFvJtpEG. #pathologists pic.twitter.com/Y9Oj9VZB9b
— CAPathologists (@Pathologists) November 19, 2018
The latest Lymphoma Daily! https://t.co/ywXQWxeb3N Thanks to @NatRevClinOncol @jato791 @OLPnews
— Jason Westin, MD FACP (@Lymphoma_Doc) February 7, 2020
R/O lymphoma
— Thomas Giordano (@Tom_J_Giordano) February 7, 2020
per @feldstej Excellent updates on Peripheral T-Cell #Lymphoma over the weekend
— Samson W. Fine, MD (@rovingatuscap) March 3, 2014
Maintenance Rituximab After R-CHOP Shows Continued Benefit in Older Patients With MCL #mcl #lymphomahttps://t.co/FPAHUVO695
— OncLive.com (@OncLive) December 23, 2019
These tweets are selected automatically with #rstats code. Please inform me if any is inappropriate. See other #HemePath pages here: https://serdarbalci.netlify.com/categories/HemePath/ or here: https://serdarbalci.wordpress.com/?s=HemePath/ See selected social media based textbook project here: http://www.patolojinotlari.com/
)